Clinical Trial Update: A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating intratumoral interleukin-2 in combination with ipilimumab for unresectable stage III–IV melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Interleukin-2 (interleukin-2)
• ipilimumab (ipilimumab)

Snippet

Sponsor: University of Utah | Conditions: Melanoma | Phase 1 | Status: COMPLETED